Abstract
The labels for statins have undergone numerous changes in recent months, with FDA adding new warnings about the potential for increased fasting plasma glucose and glycosylated hemoglobin (A1C) levels and the potential for generally nonserious and reversible cognitive adverse effects with use of statin therapy. In addition, the drug interaction section of various statins has been modified to include new contraindications and dosing restrictions when used with certain medications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
